Check out the news from the PEDIAC program: events, scientific progress, talks, public conferences etc…
Long-term support from Ligue contre le cancer to PEDIAC teams
February 28, 2023
The research projects of the PEDIAC teams are also supported by the Ligue contre le cancer, a major actor in pediatric cancer research. Here, the Ligue’s brochure “20 ans tout rond” highlights four PEDIAC teams.
Pediatric cancer: hope for better treatments for children with cancer
February 15, 2023
At the Lyon Cancer Center, M. Castets, a research fellow at Inserm, and her team are working to rethink therapeutic approaches for children. The first step is to better understand the mechanisms of resistance to treatment in young patients. This is the research focus of C. Savary, a post-doctoral researcher in M. Castets’ team.
Harnessing the MYB-dependent TAL1 5’super-enhancer for targeted therapy in T-ALL
February 3, 2023
The acquisition of genetic abnormalities leading to deregulation of oncogenes is the basis for cancer development. Some proto-oncogenes have several mechanisms of deregulation. In T-cell acute lymphoblastic leukemia (T-ALL), in V. Asnafi‘s team, C. Smith showed that patients carrying 5’super-enhancer (5’SE) mutations of the TAL1 oncogene constitute a specific subgroup of patients with a poor prognosis, independently of the level of oncogene deregulation. Interestingly, this anomaly may serve as a therapeutic target for the molecule Mebendazole.
SFH 2023 Congress
February 3, 2023
On the occasion of the congress of the French Society of Hematology from March 29 to 31, V. Asnafi will present an extended classification of T lymphoblastic leukemias.
“Cancer is a strange biological object. It is observed in virtually the entire animal and plant kingdom, and is a common disease in humans. However, at the cellular level, it is an extremely rare phenomenon. – Olivier Delattre
January 9, 2023
Discover the portrait and the interview of O. Delattre who received the 2022 INSERM Grand Prize. This pediatrician and researcher at the Institut Curie works on childhood cancers and leads the team “Diversity and plasticity of childhood tumours” of which I. Janoueix-Lerosey is a member.
High caspase 3 and vulnerability to dual BCL2 family inhibition define ETO2::GLIS2 pediatric leukemia
December 30, 2022
Pediatric acute myeloid leukemia expressing the ETO2::GLIS2 fusion oncogene is associated with a poor prognosis. In a model of inducible ETO2::GLIS2 expression, the T. Mercher team demonstrates that induction of ETO2::GLIS2 leads to increased transcription and activation of CASP3 as well as cell death. In ETO2::GLIS2 leukemic cells, a strong expression of anti-apoptotic proteins of the BCL2 family (including BCL2, BCLxL, MCL1) is observed. Functional BH3-profiling analyses showed that these cells are dependent on BCL2 and MCL1. The team targeted the activity of these two proteins with two specific inhibitors and showed, in both cell lines in vitro and in patient-derived xenograft (PDX) models in vivo, that combined treatment with both molecules is required to inhibit leukemic cell growth. This work was performed in collaboration with the CONECT-AML network led by Arnaud Petit (Hôpital Trousseau, Paris) and with the team of Patrick Auberger and Arnaud Petit (C3M, Nice).
The 2nd annual scientific committee
November 17-18, 2022
The 2nd annual scientific committee of the PEDIAC program gathered all the teams in the WHO in Lyon on November 17 and 18. All the teams presented the progress of the projects. We also discussed the priorities and perspectives for the future of the program.
7th International Workshop on the Causes of Childhood Leukemia
November 10, 2022
To advance research into the causes of childhood leukemia, the German Federal Office for Radiation Protection (BfS) has organized a 7th international workshop to be held at Kolpinghaus in Munich, November 28-30, 2022. The BfS seeks to make the workshop discussions accessible to a broad interested public and the results of previous workshops have been published. The teams of J. Schüz, J. Clavel and T. Mercher will participate to present the PEDIAC program and their scientific advances.
Presentation of work on pediatric leukemia
October 27, 2022
CHO annual meeting (Giens, France), and the
EHA Research Conference (Torre Normanna, Sicily) respectively, F. Boudia and K. Galant have presented the results of a close collaborative work between the teams of
(INSERM-Gustave Roussy-Paris Saclay) and
F. Pflumio (INSERM-CEA-Paris Saclay). Their work focus on the development of human cell-based models to study pediatric leukemias induced by the ETO2-GLIS2 fusion.
F. Boudia received one of the prize for the best oral presentations.
Parental occupational exposure to combustion products, metals, silica and asbestos and risk of childhood leukaemia: Findings from the Childhood Cancer and Leukaemia International Consortium (CLIC)
September 19, 2022
Parental occupational exposures around conception (father) or during pregnancy (mother) have been hypothesized as potential predisposing factors for childhood leukaemia. J. Schüz’s team investigated parental exposure to several known occupational carcinogens and childhood leukaemia risk.
Metabolism, hematopoietic development and splicing
September 14, 2022
The CHO (Club for Hematopoiesis and Oncogenesis) congress will be held from October 12 to 15, 2022. Among the speakers, T. Mercher and V. Maguer Satta will speak to present their projects.
4th congress “Childhood cancers: understand to treat” – React4Kids
September 10, 2022
Don’t miss the symposium entitled “Childhood cancers: understand to treat” organized by the REACT-4Kids network from October 10 to 12, 2022 in Strasbourg. O. Ayrault (WP2 coordinator of the PEDIAC program) will present the consortium.
“Septembre en Or” dedicated to the fight against pediatric cancers
September 2, 2022
On the occasion of Septembre en or, a month dedicated to the support and the fight against pediatric cancers in the world, V. Maguer Satta (WP3 coordinator of the PEDIAC program) explains in an interview the stakes of the project.
Single-cell transcriptomics reveals shared immunosuppressive landscapes of mouse and human neuroblastoma
August 20, 2022
High-risk neuroblastoma is a pediatric cancer with still a dismal prognosis, despite multimodal and intensive therapies. Tumor microenvironment represents a key component of the tumor ecosystem the complexity of which has to be accurately understood to define selective targeting opportunities, including immunebased therapies.The works of I. Janoueix’s team provides a new and precious data resource to better understand the neuroblastoma ecosystem and suggest novel therapeutic strategies, targeting both tumor cells and components of the microenvironment.
Epstein-Barr Virus Genome Deletions in Epstein-Barr Virus-Positive T/NK Cell Lymphoproliferative Diseases
July 2, 2022
The main target cells for Epstein-Barr virus (EBV) infection and persistence are B lymphocytes, although T and NK cells could also be infected. The team of S. Latour in collaboration with the team of Paul Farrell (Imperial College London) characterized the EBV present in 21 pediatric and adult patients, treated in France for a serie of diseases leading to infection of T or NK cells called “Chronic active EBV” or CAEBV. In 30% of cases, the EBV genome has large deletions that are different from one patient to another located in the vicinity of the BART region. These deletions appear and are selected independently from patient to patient. These results support the role of these deletions in these atypical forms of EBV infection.
A new work on pediatric leukemias
June 14, 2022
A work between the teams of T. Mercher U1170 and I. Plo/H. Raslova U1287 on acute megakaryoblastic leukemia of Down syndrome.
More than 110 participants at the PEDIAC seminar on “Pesticides: exposures, metabolism and toxicology”
May 31, 2022
The scientific webinar on May 31, on the topic of pesticides welcomed over 110 participants! Find out more about the topics that were discussed.
Code Against Cancer
May 31, 2022
IARC scientists including Joachim Schuz, participate at the 1st Executive Meeting of the Latin American and Caribbean Code against Cancer and are discussing scientific evidence with the goal of launching the Code on World Cancer Day 2023! The more exciting event will be the launch on World cancer day 2023.
Workshop “Pesticides: metabolism and toxicology”
March 22, 2022
Don’t miss the workshop on Tuesday, May 31 from 2 pm to 6 pm, which will focus on pesticides. Register for free to get the connecting link.
Visit of volunteers from the Aïda association to the Gustave Roussy Institute
February 16, 2022
Volunteers from the Aïda association visited the Thomas Mercher’s laboratory (Inserm U1170 Univ, Paris-Saclay, Gustave Roussy) to learn about cancer research. This association of volunteers is committed to young people affected by cancer. They participate in several missions such as helping patients, supporting research and science popularization.
WHO European report on inequalities in childhood cancer
February 15, 2022
On International Childhood Cancer Day, WHO Europe launched the report “Childhood cancer inequalities in the WHO European Region”. This report presents for the first time the evidence on child cancer inequalities in the region. Joachim Schüz is part of the advisory group that supported this work.
Understand the origins of childhood cancers
February 15, 2022
On International Childhood Cancer Day,
IARC presents a video explaining how their researchers are exploring avenues to “time travel” and study the origins of childhood cancers. More children die from childhood cancers than from any other disease. Understanding
the causes of these cancers is essential to preventing them and finding cures.
Functional screening in ETO2-GLIS2 pediatric AML
February 10, 2022
Resulting from a collaboration between the teams of Julie Chaumeil (ATIP-Avenir, Institut Cochin), Thomas Mercher and Camille Lobry (Inserm U944, Institut Saint-Louis), this study reveals the importance of a functional module
controlled by the ETO2-GLIS2 fusion oncogene, including two receptor tyrosine kinases mediating extracellular signals, in pediatric acute megakaryoblastic leukemia.
The research of Thomas Mercher’s team (Inserm U1170 Univ, Paris-Saclay, Gustave Roussy is supported by the
Ligue since 2015.
PEDIAC scientific committee
November 26, 2021
The scientific committee of the PEDIAC programme met for the first time in Paris to discuss the progress of the project.
PEDIAC is a consortium of 11 basic research teams and is funded by the French National Cancer Institute. The objective is to understand the causes and origins of cancer development at specific ages.
The challenges of the consortium, discussed in Hospimedia
September 13, 2021
Find out more about the challenges of the consortium in an interview with the scientific coordinator of PEDIAC program, in
Hospimedia, an online media on health.
“Septembre en Or”
On the occasion of Septembre en Or, the month dedicated to the fight against childhood cancer, discover the advances in pediatric oncology research at the Léon Bérard Center.
August 25 – 28, 2021
ISEH congress, Thomas Mercher will present approaches to modeling a fusion oncogene in pediatric leukemia.
Symposium on research by the INCa
June 16 – 18, 2021
Several members of PEDIAC participate in a symposium on fundamental research on pediatric cancers.
PEDIAC in the magazine Pharmaceutiques
June 3, 2021
Interview with the scientific coordinator of PEDIAC program in Pharmaceutiques, a professional magazine on overall ecosystem on health.
March 6, 2021